Cell therapies often induce harmful reactions in patients, so researchers have devised a 'safety switch' and tested it in a common procedure — the infusion of T cells in patients with blood cancers. Malcolm Brenner at Baylor College of Medicine in Houston, Texas, and his colleagues worked with T cells that are frequently given to reduce the risk of relapse and boost immune recovery after stem-cell transplantation. They modified the cells to include a gene that encodes an inducible protein crucial to cell death.
When the T cells provoked the dangerous graft-versus-host disease (GVHD) in four children with acute leukaemia, an otherwise inert drug was infused to activate the protein. Within 30 minutes, more than 90% of the T cells had been eliminated. The GVHD resolved within 24–48 hours and had not returned one year later.
Rights and permissions
About this article
Cite this article
Safety switch for cell therapy. Nature 479, 152 (2011). https://doi.org/10.1038/479152c
Published:
Issue Date:
DOI: https://doi.org/10.1038/479152c